Thematic Take

Powered by

In this section

Foreword: A growing sense of urgency in ESG

ESG 1.0 is over – get ready for ESG 2.0

How to prepare for mandatory ESG

Timeline: the past, present and future of ESG

Net-zero strategies for the pharma sector

Case studies: Leaders in the race for net zero

Q&A: GlobalData analyst on net-zero strategy for businesses

Survey: 38% of companies lack an ESG strategy

Solving sustainability challenges in rare disease trials

ESCMID 2024: The infectious consequences of climate change

How patients own tech is being used in clinical trials

Can pharma overcome generative AI’s bias problem?

China-US tensions are spilling into the biotech sector

Japanese patients among least empowered in the developed world

World Air Quality Report: what are the health impacts

Why has New Zealand U-turned on the world’s first smoking ban?

Microplastics in placentas: how serious is the problem?

In data: Pharma industry deals in the ESG theme

06/04/2024 13:18:51
  • Home | Lula’s progress plan for Brazil: A year on
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Xylem
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Project Updates
  • Trends & Insight
  • phasetwo
  • Datwyler Company Insight
  • Datwyler
  • In Depth
  • Lula’s progress plan for Brazil: A year on
  • How sham patents are hurting the pharma industry
  • Tracking the opioid lawsuit settlements amidst calls for oversight
  • Cell and gene therapy landscape in the US
  • Q&A: Cell and gene therapy value assessments need a rework to allow access
  • Pharmaceutical discovery through a gravitational lens
  • Thematic Take: ESG
  • Thematic Take: contents
  • Foreword: A growing sense of urgency in ESG
  • ESG 1.0 is over – get ready for ESG 2.0
  • ESG becomes mandatory: how to prepare
  • Theme timeline: the past, present and future of ESG
  • Net-zero strategies for the pharma sector
  • Leading pharma companies and initiatives in the race for net zero
  • GlobalData’s Christopher Papadopoullos on net-zero strategy for businesses
  • 38% of companies lack an ESG strategy – GlobalData survey
  • Sustainability challenges in rare disease trials remain, but change is happening
  • ESCMID 2024: The infectious consequences of climate change
  • Bring your own device: How patients own tech is being used in clinical trials
  • Can pharma overcome generative AI’s bias problem?
  • China-US tensions are spilling into the biotech sector
  • Japanese patients among least empowered in the developed world
  • World Air Quality Report: what are the health impacts and where is it worst?
  • Why has New Zealand U-turned on the world’s first smoking ban?
  • Microplastics in placentas: how serious is the problem?
  • Deal activity related to ESG in the pharma industry since 2021
  • GlobalData Thematic Intelligence
  • Sponsored Supplements
  • BEA Technologies
  • Cytiva
  • Listings
  • Events
  • Innovation Rankings
  • Buyer's Guides
  • Next issue
05/22/2024 00:00:00